塔拉妥单抗在未经治疗的小细胞肺癌脑转移患者中实现快速颅内缓解:真实世界病例系列
本文报告10例复发小细胞肺癌伴未经治疗脑转移患者的真实世界病例系列,其中包含症状性颅内病变及1例疑似软脑膜病变。90%的患者出现临床缓解或稳定,部分患者在多发进展性脑转移(>20个病灶)中观察到快速显著的影像学缓解和临床改善。
要点
- 塔拉妥单抗在未经治疗脑转移患者中显示临床缓解或稳定率达90%。
- 部分>20个病灶患者观察到快速显著的影像学缓解和临床改善。
- 塔拉妥单抗单药可控制颅内转移,可能避免或延迟全脑放疗。
核心结论
- 塔拉妥单抗在复发小细胞肺癌伴未经治疗脑转移患者中显示安全性和疗效,90%患者出现临床缓解或稳定。
研究设计与样本
- 真实世界病例系列,纳入10例复发小细胞肺癌伴未经治疗脑转移患者,包括症状性颅内病变及1例疑似软脑膜病变。
主要发现
- 10例患者中90%出现临床缓解或稳定。
- 部分患者(>20个病灶)观察到快速显著的影像学缓解和临床改善。
临床怎么用
- 作者认为塔拉妥单抗单药可控制颅内转移,可能避免或延迟脑放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCLC has the highest propensity for brain metastases among all malignancies. Systemic treatment for SCLC, particularly in the setting of brain metastases, is very limited. Tarlatamab, the CD3/delta-like ligand 3 bispecific T-cell engager, has changed the treatment landscape of relapsed SCLC since its Food and Drug Administration approval in May 2024. Patients with treated and stable brain metastases were included in the phase 1 DeLLphi-300 trial and phase 2 DeLLphi-301 trials of tarlatamab. Nevertheless, it remains unknown if tarlatamab is safe and efficacious in the setting of untreated, active or symptomatic brain metastases. Our case series provides, to our knowledge, the first reported evidence of the safety and efficacy of tarlatamab in patients with untreated brain metastases. In our cohort of 10 patients with relapsed SCLC and untreated brain metastases, including those with symptomatic intracranial disease and one with suspected leptomeningeal disease, clinical response or stability was seen in 90% of patients. We present several cases in which rapid, dramatic radiographic responses and clinical improvement were observed in patients with innumerable growing brain metastases (>20 lesions) who would otherwise require whole brain radiation, suggesting that tarlatamab can control intracranial metastases as monotherapy, potentially sparing or deferring the need for brain radiation.
引用
- Zhang B, Shah KB, Parma M, et al. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol. 2025. PMID: 40126456. doi:10.1016/j.jtho.2025.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。